Basic HTML Version
124
SCIENTIFIC REPORT 2012
Title:
Open multicenter study of CP-690.550 in patients with ulcerative colitis between
moderate to intense.
District Attorney:
Pfizer Inc.
Principal Investigator:
Valentí Puig Díví.
Title:
Multicenter, randomized, controlled clinical trial comparing ligation
endoscopic banding with oral carvedilol in the primary prophylaxis of hemorrhage
esophageal varices in patients with cirrhosis.
District Attorney:
CAIBER.
Principal Investigator:
Mercè Vergara Gómez.
Title:
Tivantinib randomized, double-blind, phase III clinical trial (ARQ 197) in patients
with inoperable hepatocellular carcinoma (HCC) with high MET values treated with a
systemic therapy.
District Attorney:
Daiichi Sankyo Pharma development.
Principal Investigator:
Mercè Vergara Gómez.
Title:
Subclinical inflammation and fatigue in patients with Inflammatory Bowel Disease.
District Attorney:
Own.
Principal Investigator:
Alber Villoria Ferrer.
Title:
Retrospective study of the risk of cervical dysplasia-cervical carcinoma in women with
inflammatory bowel disease. Should we increase the use of cytology?
District Attorney:
Health Consortium of Terrassa
.
Principal Investigator:
Albert Villoria Ferrer.
Title:
100-week CTBM2401C48 trial extension, phase IV, multicenter, open, with
single arm to evaluate the long-term safety of tobramycin powder for inhalation
(TIP) in patients with Cystic Fibrosis.
District Attorney:
Novartis Farmacúetica SA
Principal Investigator:
Oscar Asensio de la Cruz.